Navigation Links
Stereotaxis Announces New Management Appointment
Date:11/6/2008

Michael P. Kaminski Named Chief Executive Officer, Effective January 1,

2009

ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS), today announced a leadership transition plan under which Michael P. Kaminski, currently President and Chief Operating Officer and a member of the Board, will assume the title and responsibilities of Chief Executive Officer, effective January 1, 2009. At that time, he will replace Bevil J. Hogg, who has served as the CEO since 1997 and will remain an active member of the Company's Board of Directors.

"With the expected return of the magnetic irrigated catheter in the short term, Stereotaxis is poised to drive towards fully implementing its business plan with a strong focus on commercial success," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "We have reached a point where my own expertise in creating a new technology and the organization to support it should ideally be succeeded by a leader who brings the experience, expertise and focus necessary for operational execution and who can lead Stereotaxis to greater commercial success. Therefore, I've been working with the Board on a transition plan that involves my passing the CEO baton to Mike as of January 1, 2009. The Board and I believe that Mike has demonstrated the operational capability as well as the strategic vision to drive this company forward and achieve increasing levels of shareholder returns."

Mr. Kaminski, 48, joined Stereotaxis in April 2002 as Chief Operating Officer. Prior to coming to Stereotaxis, he spent nearly 20 years with Hill- Rom Company (Hillenbrand Industries). In his last position as Senior Vice President of North American Sales and Service, he was responsible for sales and service for the North American hospital business with revenue exceeding $750 million. Mr. Kaminski began his career at Hill-Rom in a manufacturing management position and then worked in severa
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Stereotaxis Reports Record Second Quarter Revenue
2. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
3. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
4. Stereotaxis Reports Record First Quarter Orders
5. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
6. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
7. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
8. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
9. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
10. Stereotaxis Receives $20 Million in Additional Loan Commitments
11. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 1Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 2Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 3Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 4Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 5Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 6Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 7Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 8Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 9Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 10Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 11Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 12Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 13Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 14The Minnesota Nurses Association 3A School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 60726 1The Minnesota Nurses Association 3A School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 60726 2United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 60721 1United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 60721 2